Biotech Finds Success Following Holiday Weekend

By: Dylan Sikes – AllPennyStocks.com News

Tuesday, December 26, 2023

If it’s not Artificial Intelligence (AI) related, the majority of headlines are typically talking about biotechs these days. That’s exactly what we came across this afternoon as we scanned the newswires.

A New-Jersey based biotech company saw its stock soar after it was announced the company entered into an agreement with Janssen pharmaceutica NV (a Johnson & Johnson company), whereby the company has assigned to Janssen exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radioenhancer, in China, South Korea, Singapore and Thailand.

Shares of LianBio (Nasdaq:LIAN) rallied on the news, with the price hitting $4.78/share (+6.22%) at the session high.

LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications.

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.